Learn more about whether Sanofi or Zoetis Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Sanofi (SNYNF – Research Report) received a Buy rating and price target from DZ BANK AG analyst Elmar Kraus today. The company’s shares ...

Analyst Graham Parry of Bank of America Securities reiterated a Buy rating on Sanofi (SNYNF – Research Report), boosting the price target to ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

The company projects mid to high single-digit sales growth in 2025 at constant exchange rates, excluding hyperinflation effects, and low double-digit business EPS growth before foreign exchange and ...

Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Sanofi has removed a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers of Ablynx, ...

Sanofi CFO François Roger signals increased M&A activity, eyes China for innovation, as company expects cash from Opella sale ...

The pharmaceutical company forecasts business earnings per share growth at a low double-digit percentage and plans to launch ...